Aminobisphosphonates and Toll-like receptor ligands: Recruiting Vγ9V82 T cells for the treatment of hematologic malignancy

Current Medicinal Chemistry

Volumn 18, Issue 34, 2011, Pages 5206-5216

  Kalyan, S ^a   Wesch, D ^a   Kabelitz, D ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Aminobisphosphonates; Gamma delta T cells; Hematologic cancer; Immunotherapy; Lymphoma; Myeloma; Regulatory T cells; Toll like receptor ligands

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; GERANYLTRANSFERASE; IBANDRONIC ACID; PAMIDRONIC ACID; PATTERN RECOGNITION RECEPTOR; RISEDRONIC ACID; TOLL LIKE RECEPTOR; ZOLEDRONIC ACID;

ARTICLE; CANCER IMMUNOTHERAPY; ENZYME INHIBITION; GAMMA DELTA T LYMPHOCYTE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; DIPHOSPHONATES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; LIGANDS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; TOLL-LIKE RECEPTORS;

EID: 82255195387     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798184280     Document Type: Article

References (133)

1. Saito, H.; Kranz, D. M.; Takagaki, Y.; Hayday, A. C.; Eisen, H. N.; Tonegawa, S. Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences. Nature 1984, 309, 757-762. (Pubitemid 14119426)
2. Gao, Y.; Yang, W.; Pan, M.; Scully, E.; Girardi, M.; Augenlicht, L. H.; Craft, J.; Yin, Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 2003, 198, 433-442. (Pubitemid 36976054)
3. Girardi, M.; Oppenheim, D. E.; Steele, C. R.; Lewis, J. M.; Glusac, E.; Filler, R.; Hobby, P.; Sutton, B.; Tigelaar, R. E.; Hayday, A. C. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001, 294, 605-609. (Pubitemid 32999559)
4. Kobayashi, H.; Tanaka, Y.; Nakazawa, H.; Yagi, J.; Minato, N.; Tanabe, K. A New Indicator of Favorable Prognosis in Locally Advanced Renal Cell Carcinomas: {gamma}{delta} T-Cells in Peripheral Blood. Annticancer Res. 2011, 31, 1027-1031.
5. Raspollini, M. R.; Castiglione, F.; Rossi Degl'innocenti, D.; Amunni, G.; Villanucci, A.; Garbini, F.; Baroni, G.; Taddei, G. L. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann. Oncol. 2005, 16, 590-596. (Pubitemid 40613325)
6. Godder, K. T.; Henslee-Downey, P. J.; Mehta, J.; Park, B. S.; Chiang, K. Y.; Abhyankar, S.; Lamb, L. S. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007, 39, 751-757. (Pubitemid 46901973)
7. Kabelitz, D.; Wesch, D.; Pitters, E.; Zoller, M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J. Immunol. 2004, 173, 6767-6776. (Pubitemid 39541063)
8. Rosenberg, S. A. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 2004, 350, 1461-1463. (Pubitemid 38420003)
9. Hayday, A. C. Gamma] [delta] Cells: a Right Time and a Right Place for a Conserved Third Way of Protection. Annu. Rev. Immunol. 2000, 18, 975-1026. (Pubitemid 30365402)
10. Holtmeier, W.; Kabelitz, D. gammadelta T cells link innate and adaptive immune responses. Chem. Immunol. Allergy 2005, 86, 151-183.
11. Wang, H.; Lee, H. K.; Bukowski, J. F.; Li, H.; Mariuzza, R. A.; Chen, Z. W.; Nam, K. H.; Morita, C. T. Conservation of nonpeptide antigen recognition by rhesus monkey V gamma 2V delta 2 T cells. J. Immunol. 2003, 170, 3696-3706. (Pubitemid 36359240)
12. Parker, C. M.; Groh, V.; Band, H.; Porcelli, S. A.; Morita, C.; Fabbi, M.; Glass, D.; Strominger, J. L.; Brenner, M. B. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J. Exp. Med. 1990, 171, 1597-1612. (Pubitemid 20167553)
13. Tanaka, Y.; Morita, C. T.; Tanaka, Y.; Nieves, E.; Brenner, M. B.; Bloom, B. R. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 1995, 375, 155-158.
14. Jomaa, H.; Feurle, J.; Luhs, K.; Kunzmann, V.; Tony, H. P.; Herderich, M.; Wilhelm, M. Vgamma9/Vdelta2 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis. FEMS Immunol. Med. Microbiol. 1999, 25, 371-378. (Pubitemid 29397507)
15. Hintz, M.; Reichenberg, A.; Altincicek, B.; Bahr, U.; Gschwind, R. M.; Kollas, A. K.; Beck, E.; Wiesner, J.; Eberl, M.; Jomaa, H. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett. 2001, 509, 317-322. (Pubitemid 34015963)
16. Sireci, G.; Espinosa, E.; Di Sano, C.; Dieli, F.; Fournie, J. J.; Salerno, A. Differential activation of human gammadelta cells by nonpeptide phosphoantigens. Eur. J. Immunol. 2001, 31, 1628-1635. (Pubitemid 32454712)
17. Gober, H. J.; Kistowska, M.; Angman, L.; Jeno, P.; Mori, L.; De Libero, G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 2003, 197, 163-168. (Pubitemid 36152311)
18. Sicard, H.; Al Saati, T.; Delsol, G.; Fournie, J. J. Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol. Med. 2001, 7, 711-722. (Pubitemid 33070985)
19. Morita, C. T.; Beckman, E. M.; Bukowski, J. F.; Tanaka, Y.; Band, H.; Bloom, B. R.; Golan, D. E.; Brenner, M. B. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity 1995, 3, 495-507.
20. Wrobel, P.; Shojaei, H.; Schittek, B.; Gieseler, F.; Wollenberg, B.; Kalthoff, H.; Kabelitz, D.; Wesch, D. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition. Scand. J. Immunol. 2007, 66, 320-328. (Pubitemid 47063194)
21. Fisch, P.; Meuer, E.; Pende, D.; Rothenfusser, S.; Viale, O.; Kock, S.; Ferrone, S.; Fradelizi, D.; Klein, G.; Moretta, L.; Rammensee, H. G.; Boon, T.; Coulie, P.; van der Bruggen, P. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity. Eur. J. Immunol. 1997, 27, 3368-3379. (Pubitemid 28018034)
22. Halary, F.; Peyrat, M. A.; Champagne, E.; Lopez-Botet, M.; Moretta, A.; Moretta, L.; Vie, H.; Fournie, J. J.; Bonneville, M. Control of self-reactive cytotoxic T lymphocytes expressing gamma delta T cell receptors by natural killer inhibitory receptors. Eur. J. Immunol. 1997, 27, 2812-2821. (Pubitemid 27478348)
23. Moris, A.; Rothenfusser, S.; Meuer, E.; Hangretinger, R.; Fisch, P. Role of gammadelta T cells in tumor immunity and their control by NK receptors. Microbes Infect. 1999, 1, 227-234.
24. Braud, V. M.; Allan, D. S.; O'Callaghan, C. A.; Soderstrom, K.; D'Andrea, A.; Ogg, G. S.; Lazetic, S.; Young, N. T.; Bell, J. I.; Phillips, J. H.; Lanier, L. L.; McMichael, A. J. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391, 795-799. (Pubitemid 28099678)
25. Street, S. E.; Hayakawa, Y.; Zhan, Y.; Lew, A. M.; MacGregor, D.; Jamieson, A. M.; Diefenbach, A.; Yagita, H.; Godfrey, D. I.; Smyth, M. J. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp. Med. 2004, 199, 879-884. (Pubitemid 38375207)
26. Maniar, A.; Zhang, X.; Lin, W.; Gastman, B. R.; Pauza, C. D.; Strome, S. E.; Chapoval, A. I. Human gammadelta T lymphocytes induce robust NK cellmediated antitumor cytotoxicity through CD137 engagement. Blood 2010, 116, 1726-1733.
27. Salih, H. R.; Rammensee, H. G.; Steinle, A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 2002, 169, 4098-4102. (Pubitemid 35178177)
28. *008 that is shed by tumor cells in exosomes. Cancer Res. 2010, 70, 481-489.
29. Jinushi, M.; Vanneman, M.; Munshi, N. C.; Tai, Y. T.; Prabhala, R. H.; Ritz, J.; Neuberg, D.; Anderson, K. C.; Carrasco, D. R.; Dranoff, G. MH. MHHoc. Natl. Acad. Sci. U. S. A. 2008, 105, 1285-1290.
30. Paschen, A.; Sucker, A.; Hill, B.; Moll, I.; Zapatka, M.; Nguyen, X. D.; Sim, G. C.; Gutmann, I.; Hassel, J.; Becker, J. C.; Steinle, A.; Schadendorf, D.; Ugurel, S. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin. Cancer Res. 2009, 15, 5208-5215.
31. Kabelitz, D.; Wesch, D.; He, W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007, 67, 5-8. (Pubitemid 46142752)
32. Kunzmann, V.; Wilhelm, M. Anti-lymphoma effect of gammadelta T cells. Leuk. Lymphoma 2005, 46, 671-680.
33. Wilhelm, M.; Kunzmann, V.; Eckstein, S.; Reimer, P.; Weissinger, F.; Ruediger, T.; Tony, H. P. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003, 102, 200-206. (Pubitemid 36759655)
34. Castella, B.; Vitale, C.; Coscia, M.; Massaia, M. Vgamma9Vdelta2 T cellbased immunotherapy in hematological malignancies: from bench to bedside. Cell Mol. Life Sci. 2011, 68, 2419-2432.
35. Coleman, R. E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001, 27, 165-176. (Pubitemid 32452017)
36. Bergfeld, S. A.; DeClerck, Y. A. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010, 29, 249-261.
37. Esteve, F. R.; Roodman, G. D. Pathophysiology of myeloma bone disease. Best Pract. Res. Clin. Haematol. 2007, 20, 613-624. (Pubitemid 350215377)
38. Saad, F.; Lipton, A.; Cook, R.; Chen, Y. M.; Smith, M.; Coleman, R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110, 1860-1867. (Pubitemid 47557312)
39. Berenson, J. R.; Hillner, B. E.; Kyle, R. A.; Anderson, K.; Lipton, A.; Yee, G. C.; Biermann, J. S.; American Society of Clinical Oncology Bisphosphonates Expert Panel American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Cllin. Oncol. 2002, 20, 3719-3736. (Pubitemid 34983232)
40. Luftner, D.; Henschke, P.; Possinger, K. Clinical value of bisphosphonates in cancer therapy. Anticancer Res. 2007, 27, 1759-1768. (Pubitemid 46954673)
41. Terpos, E.; Dimopoulos, M. A.; Berenson, J. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Crit. Rev. Oncol. Hematol. 2011, 77 Suppl 1, S13-23.
42. Lipton, A. Bone continuum of cancer. Am. J. Clin. Oncol. 2010, 33, S1-7.
43. Gatti, D.; Adami, S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 1999, 15, 285-296. (Pubitemid 29504951)
44. Marra, M.; Abbruzzese, A.; Addeo, R.; Del Prete, S.; Tassone, P.; Tonini, G.; Tagliaferri, P.; Santini, D.; Caraglia, M. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their antitumour effects. Curr. Cancer. Drug Targets 2009, 9, 791-800.
45. Hewitt, R. E.; Lissina, A.; Green, A. E.; Slay, E. S.; Price, D. A.; Sewell, A. K. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin. Exp. Immunol. 2005, 139, 101-111. (Pubitemid 40066134)
46. Kunzmann, V.; Bauer, E.; Feurle, J.; Weissinger, F.; Tony, H. P.; Wilhelm, M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96, 384-392. (Pubitemid 30463353)
47. Ferlazzo, V.; Sferrazza, C.; Caccamo, N.; Di Fede, G.; Di Lorenzo, G.; D'Asaro, M.; Meraviglia, S.; Dieli, F.; Rini, G.; Salerno, A. In vitro effects of aminobisphosphonates on Vgamma9Vdelta2 T cell activation and differentiation. Int. J. Immunopathol. Pharmacol. 2006, 19, 309-317. (Pubitemid 44181954)
48. Nancollas, G. H.; Tang, R.; Phipps, R. J.; Henneman, Z.; Gulde, S.; Wu, W.; Mangood, A.; Russell, R. G.; Ebetino, F. H. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38, 617-627.
49. Rogers, M. J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 2003, 9, 2643-2658. (Pubitemid 37456015)
50. Roelofs, A. J.; Thompson, K.; Gordon, S.; Rogers, M. J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 2006, 12, 6222s-6230s. (Pubitemid 44703794)
51. van Beek, E.; Pieterman, E.; Cohen, L.; Lowik, C.; Papapoulos, S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 1999, 264, 108-111. (Pubitemid 29500472)
52. Keller, R. K.; Fliesler, S. J. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Biochem. Biophys. Res. Commun. 1999, 266, 560-563. (Pubitemid 30028706)
53. Caccamo, N.; Meraviglia, S.; Cicero, G.; Gulotta, G.; Moschella, F.; Cordova, A.; Gulotta, E.; Salerno, A.; Dieli, F. Aminobisphosphonates as new weapons for gamma delta T cell-based immunotherapy of cancer. Curr. Med. Chem. 2008, 15, 1147-1153. (Pubitemid 351997804)
54. Olson, K.; Van Poznak, C. Significance and impact of bisphosphonateinduced acute phase responses. J. Oncol Pharm. Pract. 2007, 13, 223-229.
55. Kunzmann, V.; Bauer, E.; Wilhelm, M. gamma/delta T-cell stimulation by pamidronate. N Engl. J. Med. 1999, 340, 737-738.
56. Berenson, J. R.; Lichtenstein, A.; Porter, L.; Dimopoulos, M. A.; Bordoni, R.; George, S.; Lipton, A.; Keller, A.; Ballester, O.; Kovacs, M.; Blacklock, H.; Bell, R.; Simeone, J. F.; Reitsma, D. J.; Heffernan, M.; Seaman, J.; Knight, R. D. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J. Clin. Oncol. 1998, 16, 593-602. (Pubitemid 28135605)
57. Kobayashi, H.; Tanaka, Y.; Yagi, J.; Osaka, Y.; Nakazawa, H.; Uchiyama, T.; Minato, N.; Toma, H. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunology, Immunotherapy 2007, 56, 469-476. (Pubitemid 46204533)
58. Abe, Y.; Muto, M.; Nieda, M.; Nakagawa, Y.; Nicol, A.; Kaneko, T.; Goto, S.; Yokokawa, K.; Suzuki, K. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp. Hematol 2009, 37, 956-968.
59. Baccarani, M.; Saglio, G.; Goldman, J.; Hochhaus, A.; Simonsson, B.; Appelbaum, F.; Apperley, J.; Cervantes, F.; Cortes, J.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Niederwieser, D.; Silver, R.; Hehlmann, R.; European LeukemiaNet Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Bllood 2006, 108, 1809-1820. (Pubitemid 44394987)
60. Kuroda, J.; Kimura, S.; Segawa, H.; Kobayashi, Y.; Yoshikawa, T.; Urasaki, Y.; Ueda, T.; Enjo, F.; Tokuda, H.; Ottmann, O. G.; Maekawa, T. The thirdgeneration bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 2003, 102, 2229-2235. (Pubitemid 37122403)
61. D'Asaro, M.; La Mendola, C.; Di Liberto, D.; Orlando, V.; Todaro, M.; Spina, M.; Guggino, G.; Meraviglia, S.; Caccamo, N.; Messina, A.; Salerno, A.; Di Raimondo, F.; Vigneri, P.; Stassi, G.; Fournie, J. J.; Dieli, F. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronatesensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J. Immmunol 2010, 184, 3260-3268.
62. Rey, J.; Veuillen, C.; Vey, N.; Bouabdallah, R.; Olive, D. Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors. Trends Mol Med. 2009, 15, 275-284.
63. Martinet, L.; Poupot, R.; Fournie, J. J. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies. Immunol Lett. 2009, 124, 1-8.
64. Poschke, I.; Mougiakakos, D.; Kiessling, R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother. 2011, Aug; 60, 1161-1171.
65. Rabinovich, G. A.; Gabrilovich, D.; Sotomayor, E. M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol 2007, 25, 267-296. (Pubitemid 46697910)
66. Cabillic, F.; Toutirais, O.; Lavoue, V.; de La Pintiere, C. T.; Daniel, P.; Rioux-Leclerc, N.; Turlin, B.; Monkkonen, H.; Monkkonen, J.; Boudjema, K.; Catros, V.; Bouet-Toussaint, F. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother. 2010, 59, 1611-1619.
67. Castella, B.; Riganti, C.; Fiore, F.; Pantaleoni, F.; Canepari, M. E.; Peola, S.; Foglietta, M.; Palumbo, A.; Bosia, A.; Coscia, M.; Boccadoro, M.; Massaia, M. Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross Talk between Vγ9Vδ2 T Cells, αβ CD8+ T Cells, Regulatory T Cells, and Dendritic Cells. The Journal of Immunology 2011, 187, 1578-1590.
68. Yang, L.; Carbone, D. P. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 2004, 92, 13-27. (Pubitemid 39458111)
69. Whiteside, T. L.; Mandapathil, M.; Szczepanski, M.; Szajnik, M. Mechanisms of tumor escape from the immune system: Adenosineproducing Treg, exosomes and tumor-associated TLRs. Bull Cancer 2011.
70. Flavell, R. A.; Sanjabi, S.; Wrzesinski, S. H.; Licona-Limon, P. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol 2010, 10, 554-567.
71. Campbell, D. J.; Koch, M. A. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat. Rev. Immunol 2011, 11, 119-130.
72. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol 2006, 6, 295-307.
73. Kunzmann, V.; Kimmel, B.; Herrmann, T.; Einsele, H.; Wilhelm, M. Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells. Immunology 2009, 126, 256-267.
74. Wiemann, B.; Starnes, C. O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994, 64, 529-564. (Pubitemid 24381235)
75. Starnes, C. O. Coley's toxins in perspective. Nature 1992, 357, 11-12.
76. Anderson, K. V.; Bokla, L.; Nusslein-Volhard, C. Establishment of dorsalventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 1985, 42, 791-798. (Pubitemid 16083720)
77. Anderson, K. V.; Jurgens, G.; Nusslein-Volhard, C. Establishment of dorsalventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 1985, 42, 779-789. (Pubitemid 16083719)
78. Lemaitre, B.; Nicolas, E.; Michaut, L.; Reichhart, J. M.; Hoffmann, J. A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86, 973-983. (Pubitemid 26336801)
79. Medzhitov, R.; Preston-Hurlburt, P.; Janeway, C. A., Jr A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388, 394-397. (Pubitemid 27334820)
80. Poltorak, A.; He, X.; Smirnova, I.; Liu, M. Y.; Van Huffel, C.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; Freudenberg, M.; Ricciardi-Castagnoli, P.; Layton, B.; Beutler, B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282, 2085-2088. (Pubitemid 29001265)
81. Qureshi, S. T.; Lariviere, L.; Leveque, G.; Clermont, S.; Moore, K. J.; Gros, P.; Malo, D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 1999, 189, 615-625. (Pubitemid 29193362)
82. Hoshino, K.; Takeuchi, O.; Kawai, T.; Sanjo, H.; Ogawa, T.; Takeda, Y.; Takeda, K.; Akira, S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 1999, 162, 3749-3752. (Pubitemid 29314747)
83. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11, 373-384.
84. Chang, Z. L. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm. Res. 2010, 59, 791-808.
85. McGettrick, A. F.; O'Neill, L. A. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br. J. Haematol. 2007, 139, 185-193. (Pubitemid 47493098)
86. Zhang, Q.; Raoof, M.; Chen, Y.; Sumi, Y.; Sursal, T.; Junger, W.; Brohi, K.; Itagaki, K.; Hauser, C. J. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464, 104-107.
87. Yu, L.; Wang, L.; Chen, S. Endogenous toll-like receptor ligands and their biological significance. J. Cell. Mol. Med. 2010, 14, 2592-2603.
88. Fasciano, S.; Li, L. Intervention of Toll-like receptor-mediated human innate immunity and inflammation by synthetic compounds and naturally occurring products. Curr. Med. Chem. 2006, 13, 1389-1395.
89. Adams, S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009, 1, 949-964.
90. Watts, C.; West, M. A.; Zaru, R. TLR signalling regulated antigen presentation in dendritic cells. Curr. Opin. Immunol. 2010, 22, 124-130.
91. Kaisho, T.; Akira, S. Regulation of dendritic cell function through Toll-like receptors. Curr. Mol. Med. 2003, 3, 373-385. (Pubitemid 36621794)
92. Kamath, A. T.; Sheasby, C. E.; Tough, D. F. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J. Immunol. 2005, 174, 767-776. (Pubitemid 40094271)
93. Kabelitz, D. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 2007, 19, 39-45. (Pubitemid 46084902)
94. Sivori, S.; Falco, M.; Della Chiesa, M.; Carlomagno, S.; Vitale, M.; Moretta, L.; Moretta, A. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 10116-10121. (Pubitemid 38891204)
95. Shi, Y.; White, D.; He, L.; Miller, R. L.; Spaner, D. E. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res. 2007, 67, 1823-1831. (Pubitemid 46383409)
96. Spaner, D. E.; Shi, Y.; White, D.; Mena, J.; Hammond, C.; Tomic, J.; He, L.; Tomai, M. A.; Miller, R. L.; Booth, J.; Radvanyi, L. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006, 20, 286-295. (Pubitemid 43148667)
97. Oberg, H. H.; Ly, T. T.; Ussat, S.; Meyer, T.; Kabelitz, D.; Wesch, D. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J. Immunol. 2010, 184, 4733-4740.
98. Wang, H. Y.; Wang, R. F. Regulatory T cells and cancer. Curr. Opin. Immunol. 2007, 19, 217-223. (Pubitemid 46356965)
99. Peng, G.; Guo, Z.; Kiniwa, Y.; Voo, K. S.; Peng, W.; Fu, T.; Wang, D. Y.; Li, Y.; Wang, H. Y.; Wang, R. F. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005, 309, 1380-1384. (Pubitemid 41209366)
100. Pasare, C.; Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299, 1033-1036. (Pubitemid 36222922)
101. Wesch, D.; Beetz, S.; Oberg, H. H.; Marget, M.; Krengel, K.; Kabelitz, D. Direct costimulatory effect of TLR3 ligand poly (I:C) on human gamma delta T lymphocytes. J. Immunol. 2006, 176, 1348-1354. (Pubitemid 43134276)
102. Pietschmann, K.; Beetz, S.; Welte, S.; Martens, I.; Gruen, J.; Oberg, H. H.; Wesch, D.; Kabelitz, D. Toll-like receptor expression and function in subsets of human gammadelta T lymphocytes. Scand. J. Immunol. 2009, 70, 245-255.
103. Wesch, D.; Peters, C.; Oberg, H. H.; Pietschmann, K.; Kabelitz, D. Modulation of gammadelta T cell responses by TLR ligands. Cell Mol. Life Sci. 2011, 68, 2357-2370.
104. Oberg, H. H.; Juricke, M.; Kabelitz, D.; Wesch, D. Regulation of T cell activation by TLR ligands. Eur. J. Cell Biol. 2011, 90, 582-592.
105. Deetz, C. O.; Hebbeler, A. M.; Propp, N. A.; Cairo, C.; Tikhonov, I.; Pauza, C. D. Gamma interferon secretion by human Vgamma2Vdelta2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-Like receptor 2 agonist Pam3Cys. Infect. Immun. 2006, 74, 4505-4511. (Pubitemid 44157236)
106. Shrestha, N.; Ida, J. A.; Lubinski, A. S.; Pallin, M.; Kaplan, G.; Haslett, P. A. Regulation of acquired immunity by gamma delta T-cell/dendritic-cell interactions. Ann. N. Y. Acad. Sci. 2005, 1062, 79-94.
107. Devilder, M. C.; Allain, S.; Dousset, C.; Bonneville, M.; Scotet, E. Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells. J. Immunol 2009, 183, 3625-3633.
108. Naoe, M.; Ogawa, Y.; Takeshita, K.; Morita, J.; Iwamoto, S.; Miyazaki, A.; Yoshida, H. Bacillus Calmette-Guerin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. Int. J. Urol. 2007, 14, 532-8; discussion 538. (Pubitemid 46985528)
109. Devilder, M. C.; Maillet, S.; Bouyge-Moreau, I.; Donnadieu, E.; Bonneville, M.; Scotet, E. Potentiation of antigen-stimulated V gamma 9 V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J. Immunol 2006, 176, 1386-1393. (Pubitemid 43134280)
110. Rothenfusser, S.; Hornung, V.; Krug, A.; Towarowski, A.; Krieg, A. M.; Endres, S.; Hartmann, G. Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta. Eur. J. Immunol 2001, 31, 3525-3534. (Pubitemid 34030965)
111. Watanabe, N.; Narita, M.; Yokoyama, A.; Sekiguchi, A.; Saito, A.; Tochiki, N.; Furukawa, T.; Toba, K.; Aizawa, Y.; Takahashi, M. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate. Cytotherapy 2006, 8, 118-129. (Pubitemid 43675198)
112. Chauhan, D.; Singh, A. V.; Brahmandam, M.; Carrasco, R.; Bandi, M.; Hideshima, T.; Bianchi, G.; Podar, K.; Tai, Y T.; Mitsiades, C.; Raje, N.; Jaye, D. L.; Kumar, S. K.; Richardson, P.; Munshi, N.; Anderson, K. C. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer. Cell 2009, 16, 309-323.
113. Yu, L.; Chen, S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother. 2008, 57, 1271-1278.
114. Chiron, D.; Jego, G.; Pellat-Deuceunynck, C. Toll-like receptors: expression and involvement in multiple myeloma. Leuk. Res. 2010, 34, 1545-1550.
115. Shojaei, H.; Oberg, H. H.; Juricke, M.; Marischen, L.; Kunz, M.; Mundhenke, C.; Gieseler, F.; Kabelitz, D.; Wesch, D. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res. 2009, 69, 8710-8717.
116. Schmits, R.; Kundig, T. M.; Baker, D. M.; Shumaker, G.; Simard, J. J.; Duncan, G.; Wakeham, A.; Shahinian, A.; van der Heiden, A.; Bachmann, M. F.; Ohashi, P. S.; Mak, T. W.; Hickstein, D. D. LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J. Exp. Med. 1996, 183, 1415-1426. (Pubitemid 26134285)
117. Wu, N. Z.; Klitzman, B.; Dodge, R.; Dewhirst, M. W. Diminished leukocyteendothelium interaction in tumor microvessels. Cancer Res. 1992, 52, 4265-4268.
118. Spaner, D. E.; Foley, R.; Galipeau, J.; Bramson, J. Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene 2008, 27, 208-217.
119. Spaner, D. E.; Miller, R. L.; Mena, J.; Grossman, L.; Sorrenti, V.; Shi, Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leeuk. Lymphoma 2005, 46, 935-939. (Pubitemid 40959685)
120. Link, B. K.; Ballas, Z. K.; Weisdorf, D.; Wooldridge, J. E.; Bossler, A. D.; Shannon, M.; Rasmussen, W. L.; Krieg, A. M.; Weiner, G. J. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 2006, 29, 558-568. (Pubitemid 44395280)
121. Spaner, D. E.; Shi, Y.; White, D.; Shaha, S.; He, L.; Masellis, A.; Wong, K.; Gorczynski, R. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 2010, 24, 222-226.
122. Norton, J. T.; Hayashi, T.; Crain, B.; Corr, M.; Carson, D. A. Role of IL-1 receptor-associated kinase-M (IRAK-M) in priming of immune and inflammatory responses by nitrogen bisphosphonates. Proc. Natl Acad. Sci. U. S. A. 2011, 108, 11163-11168.
123. Bringmann, A.; Schmidt, S. M.; Weck, M. M.; Brauer, K. M.; von Schwarzenberg, K.; Werth, D.; Grunebach, F.; Brossart, P. Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocytederived dendritic cells. Leukemia 2007, 21, 732-738. (Pubitemid 46444557)
124. Sato, S.; Takeuchi, O.; Fujita, T.; Tomizawa, H.; Takeda, K.; Akira, S. A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and-independent pathways. Innt. Immunol 2002, 14, 783-791. (Pubitemid 34814639)
125. Killeen, S. D.; Wang, J. H.; Andrews, E. J.; Redmond, H. P. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br. J. Cancer 2006, 95, 247-252. (Pubitemid 44187583)
126. Huang, B.; Zhao, J.; Unkeless, J. C.; Feng, Z. H.; Xiong, H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008, 27, 218-224.
127. Conroy, H.; Marshall, N. A.; Mills, K. H. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008, 27, 168-180.
128. Huang, B.; Zhao, J.; Li, H.; He, K. L.; Chen, Y.; Chen, S. H.; Mayer, L.; Unkeless, J. C.; Xiong, H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005, 65, 5009-5014. (Pubitemid 40827306)
129. Liu, J.; Hamrouni, A.; Wolowiec, D.; Coiteux, V.; Kuliczkowski, K.; Hetuin, D.; Saudemont, A.; Quesnel, B. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007, 110, 296-304. (Pubitemid 47026847)
130. Kelly, M. G.; Alvero, A. B.; Chen, R.; Silasi, D. A.; Abrahams, V. M.; Chan, S.; Visintin, I.; Rutherford, T.; Mor, G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006, 66, 3859-3868.
131. Harmey, J. H.; Bucana, C. D.; Lu, W.; Byrne, A. M.; McDonnell, S.; Lynch, C.; Bouchier-Hayes, D.; Dong, Z. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer 2002, 101, 415-422.
132. Wang, J. H.; Manning, B. J.; Wu, Q. D.; Blankson, S.; Bouchier-Hayes, D.; Redmond, H. P. Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrindependent mechanism. J. Immunol. 2003, 170, 795-804. (Pubitemid 36070531)
133. Chiron, D.; Pellat-Deceunynck, C.; Amiot, M.; Bataille, R.; Jego, G. TLLmunol. 2009, 182, 4471-4478.